BIOCRYST PHARMACEUTICALS INC Logo

BIOCRYST PHARMACEUTICALS INC

Develops oral small-molecule drugs for rare diseases like hereditary angioedema.

BCRX | US

Overview

Corporate Details

ISIN(s):
US09058V1035
LEI:
Country:
United States of America
Address:
4505 EMPEROR BOULEVARD, 27703 DURHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioCryst Pharmaceuticals Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel medicines for rare diseases. The company specializes in creating oral small-molecule and protein therapeutics for patients with significant unmet medical needs, with a primary focus on hereditary angioedema (HAE) and other complement-mediated conditions. Founded in 1986, BioCryst utilizes a structure-guided drug design approach that combines biology, chemistry, and advanced technologies to develop first-in-class or best-in-class treatments. The company's mission is to improve patients' lives by advancing novel therapeutics globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BIOCRYST PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOCRYST PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOCRYST PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MAINZ BIOMED N.V. Logo
Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.
United States of America MYNZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.